Under the collaboration, FivePrime identified multiple potential therapeutic targets through screening its comprehensive proprietary protein library in cell-based assays that were focused on therapeutic pathways underlying specific immune
LIPO-102 is a new, minimally-invasive, non-ablative approach to localised fat reduction comprising an injectable aqueous combination of salmeterol xinafoate (SX) and fluticasone propionate (FP). Injection of LIPO-102 is
As per the agreement ART has granted Nihon a non-exclusive and restricted right and license to use, sell and sub-license its proprietary signal-averaging electrocardiography (SAECG) software, Predictor, customised
Cayston is administered at a dose of 75mg three times daily over a 28-day period and is delivered via the Altera Nebulizer System, a portable, drug-specific delivery device
AVAGAST is a multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate Avastin plus Xeloda (capecitabine) or 5-FU and cisplatin chemotherapy compared to Xeloda or 5-FU and
The three-year award totaling approximately $3m will support collaborative research by investigators at Sanaria and Columbia University. The new funding extends previous NIAID supported efforts at Sanaria and
Galapagos said that the Phase I studies for GLPG0259 have shown a good safety profile in healthy volunteers and confirm a once-daily oral dosing regimen. Furthermore, the studies
Source BioScience will provide infrastructure and technology platforms in addition to employing technical staff and expertise to operate the Dublin facility, with further support available from its main
The goal of the ACRG is to improve the knowledge of cancers prevalent in Asia and to accelerate drug discovery efforts by freely sharing the resulting data with
The re-examination filing provides evidence from the Phase III trial (Study 904) in relation to possible bias in the decision to re-intervene, and the validity of the endpoint.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.